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Abstract
Resistance to some cancer chemotherapeutic drugs has been identified. One strategy to overcome that 
problem is by combining two or more of the drugs to get co-chemotherapeutic effects. A derivate chalcone, 3 
- (4’-hydroxy-3’-methoxyphenyl)-1-phenyl-2-propene-1-on or para hydroxy meta methoxy chalcone (pHmMC), 
has been reported to have cytotoxic activity on some cancer cells through some pathways. The aim of this 
study was to investigate the effects of combinations of pHmMC and Doxorubicin (Dox) on the cytotoxicity, 
anti-proliferation, apoptosis, and the cell cycle of T47D (breast cancer cell-lines) in vitro. The cytotoxic and 
antiproliferative activity were determined by MTT (3-[4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium 
bromide] assay. The combination index (CI) was used to determine the synergistic, additive or antagonistic 
effects of the combinations. Flowcytometry method was performed to determine the combination effects on 
the apoptosis and cell cycle. The results indicated that the combinations had a higher inhibitory effect on the 
cell growth compared to those of single treatments of pHmMC and Dox. All the doses used in the combinations 
were lower of the single doses at their IC50s. The results showed all the combinations gave synergistic (CI: 
0.3 – 0.7) up to strong synergistic (CI: 0.1 – 0.3) effects. The synergistic effects of the combinations were due to 
increased apoptosis and induced cell cycle arrest in S and G2/M phases on the cancer cell lines.  
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Introduction
The American Cancer Society has 
reported that breast cancer is the second 
fatal cancer disease on women in the world 
(Anonymous, 2012). In Indonesia, breast 
cancer is the second most frequent one 
after cervix cancer and become the major 
caused on women mortality. The statistic 
data in 1991 reported that breast cancer 
cases reached 17.77% of all cancer cases in 
Indonesian women (Tjindarbumi, 2002). 
There are many cancer therapeutic strategies 
including surgery, chemotherapy, and 
radiation (King, 2000), but some problems 
found in the treatment. The main problems 
are the low selectivity and resistance of the 
drug on the tumor cells (Wong et al., 2006). 
Accordingly, any efforts in developing 
compounds which selectively against cancer 
are still needed. 
Doxorubic in  (Dox)  i s  a  cancer 
chemotherapeutic agent, which is given to 
various types of cancer, has been known to 
cause resistance. This compound includes in 
the anthracycline group. Besides resistance, it 
also causes cardiotoxicity in the long-term use 
(Ferreira et al., 2008). Co-chemotherapeutics 
approach is one of the alternative methods 
to resolve resistance problem. The method 
was combining the non-toxic or less toxic 
chemical with chemotherapeutic agents to 
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enhance the efficacy with a reduced toxicity 
to normal tissue (Sharma et al., 2004; Tyagi 
et al., 2004).
Chalcones are α,β−unsaturated 
ketones which have the core structure of 
1,3-difenilpropen-1-one. They have been 
studied as anti-cancer agents on different cell 
and animal models (Sasayama et al., 2007). 
One of the previous studies has reported 
that most actions of chalcones as cancer 
chemotherapeutic agents are blocking the 
cell cycle progress and inducing apoptosis 
(Hsu et al., 2006). Several kinds of literature 
also revealed that chalcones act on different 
types of targets (Boumendjel et al., 2009) 
including inhibitions of tubulin assembling 
(Ducki, 2009), angiogenesis (Mojzis et al., 
2008), and kinases (Reddy et al., 2010); as 
well as modulating of ABC proteins which 
involve in multidrug resistance (Valdameri et 
al., 2012), inductions of anti-estrogenic effect 
(Ducki, 2007) and non-apoptotic cell death 
(Robinson, et al., 2012).
Shen et al.(2007) have proved that 
the core structure of chalcones inhibits the 
activation of nuclear factor kappa (NF-κB), 
a transcription factor that is very important 
in the development and progression of 
cancer. It regulates many genes involved in 
inflammation, cell survival, cell proliferation, 
invasion, angiogenesis, and metastasis 
(Pahl, H.L., 1999). The inhibition of NF-κB 
activation causes apoptosis induction, cell 
cycle inhibition, and reduction of Bcl-XL 
expression as the downstream targets of NF-
κB in T24 and HT-1376 bladder cancer cells, 
as well as MCF-7 and MDA -MB-231 breast 
cells (Hsu et al., 2006; Guttridge et al.,1999; 
Hinz et al., 1999).
Arty (2010) has been synthesizing 
some chalcone-derivative compounds with 
a hydroxyl group at the para position. 
One derivate resulted which has structure 
of (3- (4’-hydroxy-3’-methoxyphenyl)-1-
phenyl-2-propene-1-one) named as para 
hydroxy meta methoxy chalcone (pHmMC) 
(Figure 1). The compound had cytotoxic 
activity against HeLa, Raji, T47D, and 
MCF-7 cancer cells. It was shown that it 
inhibited the proliferation of T47D and 
MCF-7 cancer cells by blocking the cell cycle 
progression. In MCF-7, pHmMC also induced 
the cell apoptosis (Arianingrum et al., 2012; 
Arianingrum et al., 2015). Interestingly, 
it did not have cytotoxic activity against 
Vero normal cell culture (Arianingrum et 
al., 2010). Based on these pHmMC’s anti-
cancer potencies, this study is to investigate 
the probable co-chemotherapeutic effect of 
pHmMC in combination with Dox. 
Figure 1. Structure of (3- (4’-hydroxy-3’-
methoxyphenyl) -1-phenyl-2-propene-1-one) 
or para hydroxy meta methoxy chalcone 
(pHmMC)
Materials  and Methods
Materials
The pHmMC was obtained from Prof 
Indyah Sulistyo Arty, Faculty of Mathematics 
and Natural Sciences, Universitas Negeri 
Yogyakarta, Indonesia. The compound was 
used as a stock solution with a concentration 
of 100 µΜ in dimethylsulfoxide (DMSO). 
The final concentration of DMSO in the 
study wells was kept less than 0.1%. 
Chemotherapeutic agent doxorubicin was 
from Kalbe, Indonesia.
Cell Cultures
T47D breast cancer cells were obtained 
from the collection of the Laboratory of 
Parasitology, Faculty of Medicine, Universitas 
Gadjah Mada, Indonesia. The cells were 
grown in a medium culture that contained 
RPMI 1640 (Gibco), 10% FBS (Gibco), 0.5% 
fungizone, and 1% penicillin-streptomycin 
(Gibco). The cells were developed at 37oC in 
a humidified atmosphere of 5% CO2/95% air. 
Trypsin-EDTA 0.025% (Gibco) was used to 
detach the cells on the flask. 
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Cytotoxic and Anti-proliferation Assay
The cytotoxic and anti-proliferation 
tests were performed using MTT colorimetric 
assay. T47D cells were seeded at a density of 
104 cells per well for the cytotoxic assay and 
5x103 cells per well for the anti-proliferative 
assay. The cells were grown for 24 hours in a 
humidified incubator at 37oC. After seeding, 
the cells were treated with solutions of 
pHmMC, Dox, and their combination. They 
were then incubated for 24 hours for the 
cytotoxic assay; and 0, 24, 48, and 72 hours for 
the antiproliferative assay. After incubations, 
the culture medium was removed and the 
cells were washed with 100 µL PBS (Sigma). 
The washed cells in the wells were added with 
100 µL of MTT (Sigma) solution (0.5 mg/ml 
diluted with RPMI medium) and incubated 
for 4 hours at 37oC. The viable cells will 
react with MTT to produce purple formazan 
crystals. A 100 µL stopper reagent (10% SDS 
(Sigma) in 0.01M HCl) was added to dissolve 
the formazan crystal. The cells were then 
incubated for 12 hours (overnight) at room 
temperature and protected from light to 
determine the absorbance of the color formed 
due to the viable cells. The absorbance of 
each well was measured using ELISA reader 
(Bio-Rad) at λ 595 nm; and it was converted 
to a percentage of viable cells (Mosmann, 
1983). The concentrations of pHmMC, Dox, 
and their combination at the IC50 were 
calculated. The co-chemotherapeutic effect 
of the combination solutions was analyzed 
using the Combination Index (CI) (Table 1) 
(Doyle and Griffith, 2000).
Table 1. Interpretation of Combination Index (CI) 
values
CI value Interpretation
<0.1 very strong synergism
0.1-0.3 strong synergism
0.3-0.7 synergism
0.7-0.9 moderate slight synergism
0.9-1.1 nearly additive 
1.1-1.45 slight to moderate antagonism
1.45-3.3 antagonism
>3.3 very strong antagonist effect
The CI was calculated based on equation 
below:
CI = D1/Dx1  + D2/Dx2
D1  :  combination concentration of pHmMC
D2 :  combination concentration of Dox
Dx1  :  concentration of pHmMC in single 
dose that could inhibit the T47D 
cells growth at the same point with 
combination concentration
Dx2  :  concentration of Dox in single dose 
that could inhibit the T47D cells 
growth at the same point with 
combination concentration
(Reynold and Meurer, 2005)
The concentrations of pHmMC and Dox 
used in the combination were referred to the 
concentration of each single compound at its 
IC50. The IC50 value of pHmMC in the previous 
study was 48 µM (Arianingrum et al., 2012); 
while the IC50 value of Dox was measured 
before the CI determination. To get a linear 
regression of Dox treatment versus viable 
T47D cells, concentrations of Dox of 7.81, 
15.63, 31.25, 62.5, 125, and 250 nM were used 
for the treatment. 
Analysis of the Apoptosis  
T47D cells were seeded and put on 
a six tissue culture well-plate at 5 x 105 
cells per well then incubated for 24 hours. 
The cells then were treated with various 
combination concentrations of pHmMC 
and Dox with each around its own IC50. 
After 24 hours incubation, the cells were 
removed using 0.25% trypsin solution, then 
were centrifuged at 2000 rpm for 3 minutes 
and washed twice with cold PBS. The cells 
were re-suspended in 500 µl of Annexin 
V buffer (Roche), then were treated with 
Annexin V and propidium iodide (PI) for 10 
minutes at room temperature and protected 
from light, then were analyzed using flow 
cytometer. The flow cytometer resulted 
four quadrants of the lower left (R1), 
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marked in blue, indicated viable cells; the 
lower right (R2), marked in green, indicated 
early apoptotic cells; the upper right (R3), 
marked in orange, indicated late apoptotic 
cells; and the upper left (R4), marked in 
yellow, indicated necrotic cells. 
Analysis of the Cell Cycle 
The washed T47D cells obtained from 
the combination treatment of pHmMC-Dox 
plate above were re-suspended in 500 µl 
of cycletestTM Plus DNA Reagent Kit (BD 
Biosciences). The Cellquest program, which 
works based on the DNA content, was used 
to calculate the percentage of the distribution 
of cells in each stage of the cell cycles (G1, S 
and G2/M phases).
Results
Cytotoxic Effect of Doxorubicin 
In this study, the IC50 of the pHmMC 
was got from the previous study of 48 µM 
(Arianingrum et al., 2012); while the IC50 of the 
Dox was got from the Dox treatment versus 
viable T47D cells. The linear regression 
of Dox-cytotoxic effect resulted (Table 2 
and Figure 2) gave the IC50 of Dox of 84 
nM. Dox treatments have also caused cells 
morphology changing as presented in 
Figure 3. Some cells appear became rounded 
and detached from the bottom flask with a 
massive morphology. The rounded shape of 
cells indicated the mortality of T47D cells. 
Figure 3. The T47D cells morphology: (A) with Dox-untreated, (B) treated with Dox at concentration of 7.8 nM, 
(C) 15.6 nM, (D) 31.3 nM, (E)125 nM, and (F)250 nM respectively. Observation of cell morphology was performed 
using inverted microscope with a magnification of 100x. The bold arrows indicate normal living cells, whereas 
the dashed arrows indicate the cell morphological changes.
Figure 2. The linear regression of the Dox cytotoxic 
effect on the T47D cells viability.
Table 2. The cytotoxic effect of Doxorubicin on T47D 
cells
Dox conc. 
treatment (nM)
Viable T47D 
cells (%)
Regression IC50
(nM)
7.8 20,767
y=-52,308x + 
150,69
R2=0.9734 84
15.6 46,140
31.3 57,854
62.5 68,690
125 94,489
250 99,814
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Figure 3.  The T47D cells morphology: (A) with Dox-untreated, (B) treated with Dox at 
concentration of 7.8 nM, (C) 15.6 nM, (D) 31.3 nM, (E)125 nM, and (F)250 nM 
respectively. Observation of cell morphology was performed using inverted 
microscope with a magnification of 100x. The bold arrows indicate normal living 
cells, whereas the dashed arrows indicate the cell morphological changes. 
 
Co-chemotherapeutic effect invitro of pHmMC-Doxorubicin on T47D cells 
a. The cytotoxic effect of the pHmMC-Dox treatment  
Several combinations of pHmMC-Dox were constructed with concentrations 
which were lower than the IC50 values of the single compounds. IC50 value of pHmMC 
from the previous study was 48 M (Arianingrum et al., 2012). The pHmMC 
concentrations used in treatment were 12; 18; 24; and 36 M, while the Dox 
concentrations were 21; 31,5; 42; and 63 nM. The cytotoxic effect of the combinations of 
pHmMC and Dox were presented in Figure 4. The data showed that the combinations 
treatment of pHmMC-Dox more decreased the viability cells compared to that of the 
single treatments of pHmMC and Dox. Treatment of 18 M pHmMC on T47D cells 
caused the cell viability of 60.97% and treatment of 31.5 nM Dox resulted in 67.08% cell 
viability. While the combination treatment at the same concentrations of the single 
compounds resulted in cell viability was 29.93%. The higher concentrations of the single 
compounds in the combination gave decreasing cell viability. In this study, the lowest 
cell viability was obtained at combination concentrations of pHmMC and Dox of 36 M 
and 63 nM respectively. 
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Figure 4. The cytotoxic effect of pHmMC-Dox combination on T47D cell. Graph (A) showed that the combination of 
pHmMC and Dox decreased cell viability compared to the single treatments. The combination treatment altered cell 
morphology: (B) untreated cells,  (C) 18 µM pHmMC, (D) 31.5 nM Dox, and (E) combination of 18 µM pHmMC and 
31.5 nM Dox.  The bold arrows indicate normal living cells, whereas the dashed arrows indicate the cell morphological 
changes. The cell morphology was observed using an inverted microscope with 100x magnification.
The changes were more apparent in line with 
increasing concentrations of Dox. 
Co-chemotherapeutic effect invitro of 
pHmMC-Doxorubicin on T47D cells
a. The cytotoxic effect of the pHmMC-Dox 
treatment 
Several combinations of pHmMC-Dox 
were constructed with concentrations which 
were lower than the IC50 values of the single 
compounds. IC50 value of pHmMC from the 
previous study was 48 µM (Arianingrum 
et al., 2012). The pHmMC concentrations 
used in treatment were 12; 18; 24; and 36 
µM, while the Dox concentrations were 21; 
31,5; 42; and 63 nM. The cytotoxic effect of 
the combinations of pHmMC and Dox were 
presented in Figure 4. The data showed that 
the combinations treatment of pHmMC-Dox 
more decreased the viability cells compared 
to that of the single treatments of pHmMC 
and Dox. Treatment of 18 µM pHmMC on 
T47D cells caused the cell viability of 60.97% 
and treatment of 31.5 nM Dox resulted in 
67.08% cell viability. While the combination 
treatment at the same concentrations of the 
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b. The combination index of the pHmMC-Dox treatment 
The co-cytotoxic effects of the combination treatments were confirmed by the CIs 
resulted (Table 3). It was indicated that the combination treatments with concentrations 
of pHmMC and Dox above respectively 18 M and 31.5 nM gave strong synergistic 
effect (CI=0.2). Combination treatments with lower concentrations of those showed 
weaker synergistic effects with CI values of 0.3, 0.4 and 0.7. The combination treatments 
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single compounds resulted in cell viability 
was 29.93%. The higher concentrations of 
the single compounds in the combination 
gave decreasing cell viability. In this study, 
the lowest cell viability was obtained at 
combination concentrations of pHmMC and 
Dox of 36 µM and 63 nM respectively.
b. The combination index of the pHmMC-
Dox treatment
The co-cytotoxic effects of the combination 
treatments were confirmed by the CIs resulted 
(Table 3). It was indicated that the combination 
treatments with concentrations of pHmMC and 
Dox above respectively 18 µM and 31.5 nM gave 
strong synergistic effect (CI=0.2). Combination 
treatments with lower concentrations of those 
showed weaker synergistic effects with CI 
values of 0.3, 0.4 and 0.7. The combination 
treatments also caused some morphological 
changes of the cells. The changes were more 
obvious in the combination treatment compared 
to the single treatments. Such changes included 
larger volume of the cells and cell nuclei, longer 
cell shape, more transparent and flat, rounded 
cell shape and cell floating. The study showed 
that the pHmMC increased the Dox-cytotoxic 
effect on the T47D cells.
c. The anti-proliferation effect of the 
pHmMC-Dox treatments
The Dox concentration used in the study 
was 21 nM, while the pHmMC concentrations 
were 18 and 24 µM. The observation results 
of the cell proliferative effect of the single 
and combination treatments are presented in 
Figure 5. The results showed that combination 
pHmMC-Dox treatments decreased the 
cell viability compared to that of the single 
treatments of pHmMC and Dox. The increase 
concentration of pHmMC or Dox in the 
combination treatment caused decreasing of 
the cell viability. All the treatments, both the 
single and the combination, decreased the 
cell viability until 48-hour incubation. After 
48 hour incubation, the single treatments at 
lower concentration (18 µM pHmMC and 21 
nM Dox 21) did not have antiproliferation 
effect so that the cells could proliferate 
and grow. While the single treatment with 
higher concentration (24 µM pHmMC) and 
the combination treatments still have an 
antiproliferative effect which inhibited the 
growth of the cells until 72-hour incubation. 
Figure 5. The inhibiting effects of pHmMC, Dox, and pHmMC-Doc 
treatments on the T47D cell proliferation.
Table 3. The combination index of the pHmMC-Dox 
treatments of on T47D cells
pHmMC
(µM)
Dox (nM)
21 31.5 42 63
12 0.7 0.4 0.4 0.3
18 0.4 0.2 0.2 0.2
24 0.3 0.2 0.2 0.2
36 0.4 0.2 0.2 0.2
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The pHmMC –Dox Combination Effect on 
Apoptosis
The concentrations of pHmMC and Dox 
used for the apoptotic effect analysis were 
half of the IC50 which were respectively 24 µM 
and 42 nM. The results showed that all the 
treatments induced apoptosis on T47D cells 
at early and late phases as shown in Figure 6. 
After treatments with the pHmMC, Dox, and 
pHmMC-Dox, the percentage of late apoptotic 
cells increased by 12.05%; 2.21%; and 21.71% 
respectively from that of the control cells 
(2.05%). The percentage of the early apoptosis 
also increased by 3.94%; 2.31%, and 6.87 % 
Figure 6. The effect of pHmMC, Dox, and their combination on T47D cells apoptosis. 
The flowcytometric profiles of (A), (B), (C), and (D) are the profiles of cell apoptosis after 
the treatments with respectively 0 µM (control), 24 µM pHmMC, 42 nM Dox, and the 
combination of 24 µM pHmMC-42 nM Dox. The Graph (E) shows the percentage of cell 
viability after the treatments. The longer the blue bar indicates the more viable cells; the 
longer the green and brown bars indicate more induce the cell apoptosis. 
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The cytotoxic activity of the pHmMC, 
either as a single treatment or in combination 
with Dox,   underwent the cell apoptosis and 
cell cycle arrest. 
Studies on chalcones have been 
reported that apoptotic mechanism of the 
chalcones’ treatments are occurred through 
mitochondrial pathway and inhibiting of 
NF-κB (Hsu et al., 2006; Shen et al., 2007; 
and Yadav et al., 2011); through increasing 
transcription of Bcl-2 that prevents the release 
of cytochrome c by Bax in mitochondria. The 
inhibition of NF-κB also causes decreasing 
of Bcl-2 and Bcl-XL expressions, two main 
anti-apoptotic proteins (Simstein et al., 2003). 
These mechanisms might be responsible for 
the apoptotic induction of pHmMC. 
The single treatment of pHmMC 
induced cell arrest at G2/M phase. This 
result is consistent with the previous research 
(Arianingrum et al, 2012). While the Dox and 
pHmMC-Dox combination treatments induced 
cell arrest at S and G2/M phase. Various 
studies have shown that some chalcones 
inhibited cell cycle (Yadav et al., 2011). Some 
literature suggests that chalcones’ ability to 
inhibit the cell cycle by inhibiting cell division 
cycle25B (Cdc25B) phosphatase (Zhang et al., 
2014 and Yuan et al., 2014). Cdc25B is a mitotic 
regulator that acts as a ‘starter phosphatase’ to 
initiate the positive feedback loop at the entry 
into M phase. The activity of Cdc25B appears 
during late S phase and peaks during G2 phase. 
Both in-vitro and in vivo cdc25B is activated 
through phosphorylation during S-phase. 
Inhibition of phosphatase results in inhibition 
of cell cycle in G2/S-phase and mitotic arrest 
occurs (Lammer et al., 1998; Nilsson et al., 2000, 
and Lindgvist et al., 2005). While some study 
about Dox mention that Dox damaged double 
stranded DNA by intercalation on DNA base 
pairs and inhibition topoisomerase IIa. DNA 
damage will activate kinase protein (ATM), 
and this will further activate Chk2. Activation 
of Chk2 will cause Cdc25 inactive which in 
turn inhibit as cdc2. Both proteins are needed 
in G and M phase of cell cycle. Inactivation of 
these proteins will lead to G2/M arrest in the 
respectively from the control cells (2.09%). 
Compared with the single treatments, the 
combination treatments more induced the 
cell apoptosis. 
pHmMC –Dox Combination Effect on cell 
cycle progression 
The concentrations of the pHmMC and 
Dox used for analyzing the combination 
treatment effect on the T47D cell cycle were 
the same as the doses for the apoptosis 
study (24 µM pHmMC, 42 nM Dox, and their 
combination). Table 4 shows the distribution 
cells into cell cycle phases of Go-G1, S, and 
G2/M after the treatments. It shows that 
the single treatments of pHmMC and Dox 
inhibited the cell cycle and caused the cells 
arrest at G2/M, which were higher than 
that of the cell control. The pHmMC-Dox 
combination caused cells accumulation in S 
and G2/M phase. 
Table 4.  The inhibiting effects of pHmMC, Dox, and 
pHmMC-Doc treatments on the T47D cell cycle
Treatment
The Percentage of 
T47D cells (%) in 
phase :
G0-G1 S G2/M
Untreated 59.96 22.51 16.72
24 µM pHmMC 47.88 18.41 29.08
42 nM Dox 25.99 24.98 47.61
24 µM pHmMC- 42 nM Dox 26.73 31.99 40.66
Discussion 
From the study results, it was concluded 
that the pHmMC increased the Dox efficacy 
in vitro on T47D breast cancer cells. The CI 
study showed that the combination treatment 
of pHmMC-Dox had a synergistic effect 
up to strong synergy; especially at the low 
concentrations (below IC50). The combination 
treatments also gave better anti-proliferative 
effect than that of the single ones. Those 
above facts confirmed that combining Dox 
with pHmMC could reduce the dosage of the 
Dox.  This will give the benefit of minimizing 
the cytotoxic effects of the treatment to the 
normal cells.  
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cell cycle (Drummond, 2007). Combination 
treatment of pHmMC and Dox caused cell cycle 
arrest in S and G2/M. Combination treatment 
also decreased the cell population. Based on the 
research, pHmMC could improve Dox cytotoxic 
effect by increasing the inhibition of cell cycle 
arrest from G2-M to S phase. 
Conclusion 
The combination treatments of the 
pHmMC-Dox resulted in a synergistic up 
to strong synergistic effect, an increase in 
apoptosis, and induction of the cell cycle 
arrest in S and G2/M phase of T47D cancer 
cells. The combination treatment of pHmMC-
Dox is potential to be developed as a breast 
cancer therapy. 
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